Journal of Hepatology
Volume 51, Issue 5 , Pages 939-948 , November 2009

The long and winding road leading to the identification of the hepatitis C virus

  • Michael Houghton

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 510 289 0881; fax: +1 925 743 0660.

References 

  1. Krugman S, Ward R, Giles JP. The natural history of infectious hepatitis. Am J Med. 1962;32:717–728
  2. Feinstone SM, Kapikian AZ, Purcell RH. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science. 1973;182:1026–1028
  3. Bayer ME, Blumberg BS, Werner B. Particles associated with Australia antigen in the sera of patients with leukaemia, Down’s Syndrome and hepatitis. Nature. 1968;218:1057–1059
  4. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med. 1975;292:767–770
  5. Alter HJ, Purcell RH, Holland PV, Popper H. Transmissible agent in non-A, non-B hepatitis. Lancet. 1978;1:459–463
  6. Hollinger FB, Gitnick GL, Aach RD, Szmuness W, Mosley JW, Stevens CE, et al. Non-A, non-B hepatitis transmission in chimpanzees: a project of the transfusion-transmitted viruses study group. Intervirology. 1978;10:60–68
  7. Shimizu YK, Feinstone SM, Purcell RH, Alter HJ, London WT. Non-A, non-B hepatitis: ultrastructural evidence for two agents in experimentally infected chimpanzees. Science. 1979;205:197–200
  8. Bradley DW, Maynard JE, Popper H, Cook EH, Ebert JW, McCaustland KA, et al. Posttransfusion non-A, non-B hepatitis: physicochemical properties of two distinct agents. J Infect Dis. 1983;148:254–265
  9. Feinstone SM, Mihalik KB, Kamimura T, Alter HJ, London WT, Purcell RH. Inactivation of hepatitis B virus and non-A, non-B hepatitis by chloroform. Infect Immun. 1983;41:816–821
  10. Bradley DW. The agents of non-A, non-B viral hepatitis. J Virol Methods. 1985;10:307–319
  11. He LF, Alling D, Popkin T, Shapiro M, Alter HJ, Purcell RH. Determining the size of non-A, non-B hepatitis virus by filtration. J Infect Dis. 1987;156:636–640
  12. Dienstag JL, Alter HJ. Non-A, non-B hepatitis: evolving epidemiologic and clinical perspective. Semin Liver Dis. 1986;6:67–68
  13. Seeff LB, Dienstag JL. Transfusion-associated non-A, non-B hepatitis. Where do we go from here?. Gastroenterology. 1988;95:530–533
  14. Alter HJ. The dominant role of non-A, non-B in the pathogenesis of post-transfusion hepatitis: a clinical assessment. Clin Gastroenterol. 1980;9:155–170
  15. Hollinger FB, Mosley JW, Szmuness W, Aach RD, Peters RL, Stevens C. Transfusion-transmitted viruses study: experimental evidence for two non-A, non-B, hepatitis agents. J Infect Dis. 1980;142:400–407
  16. Alter MJ, Hadler SC, Francis DP, Maynard JE. The epidemiology of non-A, non-B hepatitis in the United States. Prog Clin Biol Res. 1985;182:71–719
  17. Shih JW, Mur JI, Alter HJ. Non-A, non-B hepatitis: advances and unfulfilled expectations of the first decade. Prog Liver Dis. 1986;8:433–452
  18. Houghton M, Stewart AG, Doel SM, Emtage JS, Eaton MA, Smith JC, et al. The amino-terminal sequence of human fibroblast interferon as deduced from reverse transcripts obtained using synthetic oligonucleotide primers. Nucleic Acids Res. 1980;8:1913–1931
  19. Houghton M, Jackson IJ, Porter AG, Doel SM, Catlin GH, Barber C, et al. The absence of introns within a human fibroblast interferon gene. Nucleic Acids Res. 1981;9:247–266
  20. Rizzetto M, Canese MG, Aricò S, Crivelli O, Trepo C, Bonino F, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;12:997–1003
  21. Rizzetto M, Verme G. Delta hepatitis–present status. J Hepatol. 1985;1:187–193
  22. Denniston KJ, Hoyer BH, Smedile A, Wells FV, Nelson J, Gerin JL. Cloned fragment of the hepatitis delta virus RNA genome: sequence and diagnostic application. Science. 1986;232:873–875
  23. Kamimura T, Ponzetto A, Bonino F, Feinstone SM, Gerin JL, Purcell RH. Cytoplasmic tubular structures in liver of HBsAg carrier chimpanzees infected with delta agent and comparison with cytoplasmic structures in non-A, non-B hepatitis. Hepatology. 1983;3:631–637
  24. Wang KS, Choo QL, Weiner AJ, Ou JH, Najarian RC, Thayer RM, et al. Structure, sequence and expression of the hepatitis delta (delta) viral genome. Nature. 1986;323:508–514[Erratum in: Nature 1987;5:328, 456]
  25. Weiner AJ, Choo QL, Wang KS, Govindarajan S, Redeker AG, Gerin JL, et al. A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta. J Virol. 1988;62:594–599
  26. Weiner AJ, Wang KS, Choo QL, Gerin JL, Bradley DW, Houghton M. Hepatitis delta (delta) cDNA clones: undetectable hybridization to nucleic acids from infectious non-A, non-B hepatitis materials and hepatitis B DNA. J Med Virol. 1987;21:239–247
  27. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005;11(7):791–796[Epub 2005 Jun 12. Erratum in: Nat Med 2005;11:905]
  28. Seto B, Coleman WG, Iwarson S, Gerety RJ. Detection of reverse transcriptase activity in association with the non-A, non-B hepatitis agent(s). Lancet. 1984;8409:941–943
  29. Prince AM, Huima T, Williams BA, Bardina L, Brotman B. Isolation of a virus from chimpanzee liver cell cultures inoculated with sera containing the agent of non-A, non-B hepatitis. Lancet. 1984;8411:1071–1075
  30. Shimizu YK, Oomura M, Abe K, Uno M, Yamada E, Ono Y, et al. Production of antibody associated with non-A, non-B hepatitis in a chimpanzee lymphoblastoid cell line established by in vitro transformation with Epstein–Barr virus. Proc Natl Acad Sci USA. 1985;82:2138–2142
  31. Maeda T, Honda Y, Hanawa M, Yamada E, Ono Y, Shikata T, et al. Production of antibodies directed against microtubular aggregates in hepatocytes of chimpanzees with non-A, non-B hepatitis. J Gen Virol. 1989;70(Pt. 6):1401–1407
  32. Broome S, Gilbert W. Immunological screening method to detect specific translation products. Proc Natl Acad Sci USA. 1978;75:2746–2749
  33. Young RA, Davis RW. Efficient isolation of genes by using antibody probes. Proc Natl Acad Sci USA. 1983;80:1194–1198
  34. Bradley DW. Hepatitis non-A, non-B viruses become identified as hepatitis C and E viruses. Prog Med Virol. 1990;37:101–135
  35. Feinstone SM, Alter HJ, Dienes HP, Shimizu Y, Popper H, Blackmore D, et al. Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis. 1981;144:588–598
  36. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood–borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–362
  37. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989;244:362–364
  38. Miyamura T, Saito I, Katayama T, Kikuchi S, Tateda A, Houghton M, et al. Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis. Proc Natl Acad Sci USA. 1990;87:983–987
  39. Kubo Y, Takeuchi K, Boonmar S, Katayama T, Choo QL, Kuo G, et al. A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan. Nucleic Acids Res. 1989;17:1367–1372
  40. Simmonds P. Variability of hepatitis C virus. Hepatology. 1995;21:570–583
  41. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol. 1998;143:2493–2503
  42. Patel K, McHutchison JG. Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. Cleve Clin J Med. 2004;71(Suppl. 3):S8–S12
  43. Bukh J, Purcell RH, Miller RH. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci USA. 1994;91:8239–8243
  44. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA. 1991;88:2451–2455
  45. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA. 1990;87:9524–9528
  46. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol. 1993;67:2832–2843
  47. Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol. 1993;67:4665–4675
  48. Eckart MR, Selby M, Masiarz F, Lee C, Berger K, Crawford K, et al. The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochem Biophys Res Commun. 1993;192:399–406
  49. Suzich JA, Tamura JK, Palmer-Hill F, Warrener P, Grakoui A, Rice CM, et al. Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes. J Virol. 1993;67:6152–6158
  50. Lohmann V, Körner F, Herian U, Bartenschlager R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol. 1997;71:8416–8428
  51. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110–113
  52. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science. 2000;290:1972–1974
  53. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci USA. 1993;90:10583–10587
  54. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol. 2007;81:8374–8383
  55. Griffin SD, Beales LP, Clarke DS, Worsfold O, Evans SD, Jaeger J, et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett. 2003;535:34–38
  56. Luik P, Chew C, Aittoniemi J, Chang J, Wentworth P, Dwek RA, et al. The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy. Proc Natl Acad Sci USA. 2009;106:12567–12568
  57. Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog. 2007;7:e103
  58. Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog. 2008;4:e1000032
  59. Einav S, Gerber D, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, et al. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol. 2008;9:1019–1027
  60. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci USA. 2007;104:12884–12889
  61. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell. 2005;19:111–122
  62. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology. 2005;129:1031–1041
  63. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science. 1998;5390:938–941
  64. McKeating JA, Zhang LQ, Logvinoff C, Flint M, Zhang J, Yu J, et al. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol. 2004;78:8496–8505
  65. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology. 2007;46:1722–1731
  66. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature. 2007;446:801–805
  67. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature. 2009;457:882–886
  68. Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D’Oro U, et al. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA. 2005;102:18544–185449
  69. Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood. 2001;98:3745–3749
  70. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet. 1994;343:388–390
  71. Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, Inchauspé G. Immunity in hepatitis C infection. J Infect Dis. 1992;165:438–443
  72. Weiner AJ, Paliard X, Selby MJ, Medina-Selby A, Coit D, Nguyen S, et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol. 2001;75:7142–7148
  73. Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology. 2001;33:1479–1487
  74. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA. 1994;91:1294–1298
  75. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature. 2005;436:961–966
  76. Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K, Dong C, et al. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine. 2007;257773–257784
  77. Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med. 2006;12190–12197
  78. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436–2441
  79. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44:102–107
  80. Crotta S, Stilla A, Wack A, D’Andrea A, Nuti S, D’Oro U, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med. 2002;195:35–41
  81. Tseng C, Klimpel G. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer functions. J Exp Med. 2002;195:43–49
  82. Loo YM, Gale M. Viral regulation and evasion of the host response. Curr Top Microbiol Immunol. 2007;316:295–313
  83. Bowen DG, Walker CM. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med. 2005;201:1709–1714
  84. Hijikata M, Shimizu YK, Kato H, Iwamoto A, Shih JW, Alter HJ, et al. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol. 1993;67:1953–1958
  85. Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris HJ, et al. Hepatitis C virus cell–cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology. 2008;47:17–24
  86. Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, Angus AG, et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol. 2009;90:48–58
  87. Crispe N. Mechanisms of self-tolerance. Immunol Today. 1988;9:329–331
  88. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5:453–463

☆ The author declared that he does not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00535-2

doi: 10.1016/j.jhep.2009.08.004

Journal of Hepatology
Volume 51, Issue 5 , Pages 939-948 , November 2009

Article Tools

* Image Usage & Resolution